Cutaneous lymphoma

Trial Name

Description

Click for more information (external page)

RESMAIN

Phase 2 study testing resminostat as treatment for people with mycosis fungoides (MF) or Sézary syndrome (SS), a type of cutaneous (skin) T-cell lymphoma.

Suitable for patients who have received treatment and their lymphoma is stable or in remission

PORT

Phase 2 study testing the use of radiotherapy in addition to pembrolizumab for people with mycosis fungoides (MF) or Sézary syndrome (SS), a type of cutaneous (skin) T-cell lymphoma

Suitable for patients with lymphoma which has come back after previous treatment

CDK-003-101

A phase 1 trial of CDK-003 in patients with relapsed or refractory cutaneous T-cell lymphoma.